Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2010-023977-21 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The benefit of using platelet rich plasma (PRP) in cartilage injuries, and specifically in degenerative ones, has not been assessed yet. Current studies on the PRP healing or repairing effect on knee cartilage degenerative injuries are not conclusive to establish a standard of behavior, although PRP has shown to improve joint functionality and reduce pain.
Hypothesis: PRP intra-articular injections in osteoarthritic knees reduces pain and leads to a more effective and lasting functional recovering than corticosteroid intra-articular injections.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| platelet-rich plasma intra-articular knee injections | Experimental | a single intra-articular injection of PRP in knee osteoarthritis |
|
| Corticosteroid intra-articular knee injections | Active Comparator | a betamethasone and bupivacaine intra-articular injection |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| platelet-rich plasma | Biological | a single intra-articular injection |
|
| Measure | Description | Time Frame |
|---|---|---|
| The value of the visual analogue scale pain (VAS) | The difference between the baseline and the value of the scale one month after treatment | one month after the treatment |
| Measure | Description | Time Frame |
|---|---|---|
| the value of pain visual analog scale according to | 4 weeks, 3 and 6 months after treatment | |
| the functional level of the knee KOOS | 4 weeks, 3 and 6 months after treatment | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nayana Joshi, MD | Hospital Vall d'Hebron | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Universitario Vall d'Hebron | Barcelona | Barcelona | 08035 | Spain |
Not provided
| ID | Term |
|---|---|
| D020370 | Osteoarthritis, Knee |
| ID | Term |
|---|---|
| D010003 | Osteoarthritis |
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000305 | Adrenal Cortex Hormones |
| ID | Term |
|---|---|
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Corticosteroid | Drug | A single betamethasone and bupivacaine intra-articular injection |
|
| All reported adverse events |
| 4 weeks, 3 and 6 months after treatment |
| Scale of the SF36 quality of life | 4 weeks, 3 and 6 months after treatment |
| D012216 |
| Rheumatic Diseases |